



# SAFETY DATA SHEET

Revision date: 19-Mar-2015

Version: 3.0

Page 1 of 12

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Tolterodine Tartrate Modified Release Capsules

**Trade Name:** Detrol LA; Detrusitol LA; Detrol SR, Detrusitol SR; Santizor; Santizor XL; Tolterodin Pfizer; Urotrol Neo

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used for overactive bladder

### Details of the Supplier of the Safety Data Sheet

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

**Emergency telephone number:**  
**CHEMTREC (24 hours):** 1-800-424-9300  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours):** +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Reproductive Toxicity: Category 2

#### EU Classification:

EU Indication of danger: Not classified

### Label Elements

**Signal Word:** Warning  
**Hazard Statements:** H361d - Suspected of damaging the unborn child

**Precautionary Statements:** P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations

## SAFETY DATA SHEET

**Material Name: Tolterodine Tartrate Modified Release Capsules**  
**Revision date: 19-Mar-2015**

**Page 2 of 12**

**Version: 3.0**



**Other Hazards** No data available  
**Australian Hazard Classification (NOHSC):** Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

**Hazardous**

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*
Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*
Tolterodine L-Tartrate	124937-52-6	Not Listed	Repr. Cat. 3;R63 N;R51/53	Repr. 2 (H361d) Aquatic Acute 2 (H401) Aquatic Chronic 2 (H411)	2
Propylene glycol	57-55-6	200-338-0	Not Listed	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	Not Listed	*
Oleic acid	112-80-1	204-007-1	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	Not Listed	*
Ethylcellulose	9004-57-3	Not Listed	Not Listed	Not Listed	*
Medium Chain Fatty Acid Triglyceride	Unassigned	Not Listed	Not Listed	Not Listed	*
Ferric oxide yellow	51274-00-1	257-098-5	Not Listed	Not Listed	*
Shellac	9000-59-3	232-549-9	Not Listed	Not Listed	*
Simethicone	8050-81-5	Not Listed	Not Listed	Not Listed	*
FD&C Blue No. 2	860-22-0	212-728-8	Not Listed	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	Not Listed	*

**Additional Information:** \* Proprietary  
 Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.  
 In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

**For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16**

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 3 of 12

Version: 3.0

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

- Eye Contact:** Flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
- Skin Contact:** Wash skin with soap and water. If irritation occurs or persists, get medical attention.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

- Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
- Medical Conditions Aggravated by Exposure:** None known

#### Indication of the Immediate Medical Attention and Special Treatment Needed

- Notes to Physician:** None

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

#### Special Hazards Arising from the Substance or Mixture

- Hazardous Combustion Products:** Emits toxic fumes of carbon monoxide and nitrogen oxide.
- Fire / Explosion Hazards:** Not applicable

#### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

- Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
- Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

#### Precautions for Safe Handling

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 4 of 12

Version: 3.0

### 7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

#### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.  
**Specific end use(s):** Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Estonia OEL - TWA	10 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
Latvia OEL - TWA	5 mg/m <sup>3</sup>
Lithuania OEL - TWA	10 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Slovakia OEL - TWA	6 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>

#### Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	4.0 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
Ireland OEL - TWAs	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Slovakia OEL - TWA	4 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Switzerland OEL - TWAs	3 mg/m <sup>3</sup>

#### Tolterodine L-Tartrate

Pfizer OEL TWA-8 Hr:	25µg/m <sup>3</sup>
----------------------	---------------------

#### Propylene glycol

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 5 of 12

Version: 3.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Australia TWA	150 ppm 474 mg/m <sup>3</sup> 10 mg/m <sup>3</sup>
Ireland OEL - TWAs	150 ppm 470 mg/m <sup>3</sup> 10 mg/m <sup>3</sup>
Latvia OEL - TWA	7 mg/m <sup>3</sup>
Lithuania OEL - TWA	7 mg/m <sup>3</sup>

#### Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Denmark OEL - TWA	6 mg/m <sup>3</sup>
Estonia OEL - TWA	5 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup> 5 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup> 4 mg/m <sup>3</sup>
Latvia OEL - TWA	10 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Poland OEL - TWA	10.0 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Romania OEL - TWA	10 mg/m <sup>3</sup>
Russia OEL - TWA	10 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Sweden OEL - TWAs	5 mg/m <sup>3</sup>
Switzerland OEL - TWAs	3 mg/m <sup>3</sup>
Vietnam OEL - TWAs	6 mg/m <sup>3</sup> 5 mg/m <sup>3</sup>

#### Oleic acid

Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
--------------------	------------------------

#### Simethicone

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

#### Analytical Method: Exposure Controls

Analytical method available for tolterodine. Contact Pfizer Inc for further information.

#### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

#### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

#### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 6 of 12

Version: 3.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Eyes:** Wear safety glasses or goggles if eye contact is possible.  
**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.  
**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Capsule	<b>Color:</b>	No data available.
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

**Solvent Solubility:** No data available  
**Water Solubility:** No data available  
**pH:** No data available.  
**Melting/Freezing Point (°C):** No data available  
**Boiling Point (°C):** No data available.  
**Partition Coefficient: (Method, pH, Endpoint, Value)**

#### Gelatin

No data available

#### FD&C Blue No. 2

No data available

#### Ethylcellulose

No data available

#### Hydroxypropyl methylcellulose

No data available

#### Medium Chain Fatty Acid Triglyceride

No data available

#### Oleic acid

No data available

#### Starch

No data available

#### Sucrose

No data available

#### Shellac

No data available

#### Titanium dioxide

No data available

#### Simethicone

No data available

#### Ferric oxide yellow

No data available

#### Propylene glycol

No data available

#### Tolterodine L-Tartrate

Predicted Log P 5.24

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 7 of 12

Version: 3.0

### Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

## 10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

## 11. TOXICOLOGICAL INFORMATION

### Information on Toxicological Effects

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Short Term:	Accidental ingestion may cause effects similar to those seen in clinical use.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on fetus.
Known Clinical Effects:	May cause effects similar to those seen in clinical use including dry mouth, blurred vision, constipation, and upset stomach.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### FD&C Blue No. 2

Rat	Oral	LD50	2 g/kg
Mouse	Oral	LD50	2500mg/kg

#### Hydroxypropyl methylcellulose

Rat	Oral	LD50	> 10,000 mg/kg
-----	------	------	----------------

#### Sucrose

Rat	Oral	LD50	29.7 g/kg
-----	------	------	-----------

#### Titanium dioxide

Rat	Oral	LD50	> 7500 mg/kg
Rat	Subcutaneous	LD50	50 mg/kg

#### Propylene glycol

Rat	Oral	LD 50	22,000 mg/kg
Mouse	Oral	LD 50	24,900mg/kg
Rabbit	Dermal	LD 50	20,800mg/kg

#### Tolterodine L-Tartrate

Mouse	Oral	LD 50	> 200 mg/kg
-------	------	-------	-------------

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 8 of 12

Version: 3.0

### 11. TOXICOLOGICAL INFORMATION

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Propylene glycol

Skin Irritation Rabbit Mild  
Eye Irritation Rabbit Mild

##### Tolterodine L-Tartrate

Skin Irritation Rabbit Non-irritating  
Skin Sensitization - GPMT Guinea Pig No effect

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Tolterodine L-Tartrate

26 Week(s) Mouse Oral 10 mg/kg/day NOEL None identified  
52 Week(s) Dog Oral 0.5 mg/kg/day NOEL None identified

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Tolterodine L-Tartrate

Reproductive & Fertility-Females Mouse Oral 20 mg/kg/day NOEL No effects at maximum dose  
Reproductive & Fertility-Males Mouse Oral 30 mg/kg/day NOEL No effects at maximum dose  
Embryo / Fetal Development Mouse Oral 20 mg/kg/day NOEL Embryotoxicity, Teratogenic

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### FD&C Blue No. 2

Bacterial Mutagenicity (Ames) *Salmonella* Negative

##### Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

##### Tolterodine L-Tartrate

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative  
*In Vivo* Chromosome Aberration Human Lymphocytes Negative  
*In Vivo* Micronucleus Mouse Negative

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Tolterodine L-Tartrate

Not specified Mouse Oral 30 mg/kg/day Maximally Tolerated Dose Not carcinogenic

#### Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

##### Titanium dioxide

###### IARC:

Group 2B (Possibly Carcinogenic to Humans)

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 9 of 12

Version: 3.0

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** This mixture contains material that is toxic to aquatic life. See Aquatic toxicity data of the active ingredient, below:

**Toxicity:**

#### **Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

##### **Tolterodine L-Tartrate**

*Daphnia magna* (Water Flea) OECD LC50 48 Hours 1.7 mg/L  
*Pseudokirchneriella subcapitata* (Green Alga) EC50 72 Hours 20 mg/L

**Persistence and Degradability:** No data available

##### **Bio-accumulative Potential:**

**Partition Coefficient: (Method, pH, Endpoint, Value)**

##### **Tolterodine L-Tartrate**

Predicted Log P 5.24

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

**Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture**

**Canada - WHMIS: Classifications**

# SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 10 of 12

Version: 3.0

## 15. REGULATORY INFORMATION

### WHMIS hazard class:

Class D, Division 2, Subdivision A



### Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

### Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

### Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

### Tolterodine L-Tartrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

### Ethylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

### Medium Chain Fatty Acid Triglyceride

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 11 of 12

Version: 3.0

### 15. REGULATORY INFORMATION

California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
<b>Ferric oxide yellow</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	257-098-5
<b>Propylene glycol</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-338-0
<b>Shellac</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-549-9
<b>Simethicone</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
<b>Titanium dioxide</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
<b>Oleic acid</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-007-1
<b>FD&amp;C Blue No. 2</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	212-728-8

## SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release  
Capsules  
Revision date: 19-Mar-2015

Page 12 of 12

Version: 3.0

### 15. REGULATORY INFORMATION

#### Gelatin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6

### 16. OTHER INFORMATION

#### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child  
Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life  
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

Toxic to Reproduction: Category 2  
N - Dangerous for the environment

R63 - Possible risk of harm to the unborn child.  
R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

**Data Sources:** Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

**Revision date:** 19-Mar-2015

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**